This legislation aims to enhance the early detection and prevention of cardiovascular disease, which is identified as the leading cause of death in the United States. It mandates coverage for specific advanced lipid panel tests, including lipoprotein(a) (Lp(a)) and apolipoprotein B (ApoB) levels. The bill highlights that routine cholesterol panels often fail to detect these crucial markers, which are considered better predictors of cardiovascular risk than LDL cholesterol alone, with a substantial portion of Americans having elevated Lp(a) levels. The bill requires that these essential cardiovascular tests be covered without any cost-sharing for individuals presenting with specific risk factors. These risk factors include a family history of premature cardiovascular disease, a personal history of myocardial infarction or stroke, elevated LDL cholesterol, or a diagnosis of diabetes mellitus or obesity. The coverage mandate extends across group health plans , individual health insurance coverage , and the federal Medicare and Medicaid programs, aiming to ensure broad access to these diagnostic tools for at-risk populations.